readthroughSign in
Nov 16, 2026Trial update

UC Davis-led trial of Zynlonta combination in DLBCL marked suspended as of Nov. 16 update

The phase 2 study testing loncastuximab tesirine and rituximab followed by DA-EPOCH-R in high-risk diffuse large B-cell lymphoma is on hold pending enrollment allocation.

A phase 2 trial evaluating loncastuximab tesirine and rituximab, followed by dose-adjusted DA-EPOCH-R chemotherapy, in previously untreated high-risk diffuse large B-cell lymphoma has a status of suspended as of the last update posted November 16, 2026, with the reason listed as "Pending enrollment allocation."1

The study, registered under NCT05600686 with sponsor ID UCDCC#303, is led by the University of California, Davis, with the National Cancer Institute and ADC Therapeutics S.A. listed as collaborators. The trial started on May 24, 2023, with an estimated primary completion date of May 1, 2027, and an estimated study completion date of December 15, 2027. It was first posted on October 31, 2022.1

The regimen combines loncastuximab tesirine, an antibody-drug conjugate, with rituximab, followed by DA-EPOCH-R. According to the trial description, loncastuximab tesirine is a monoclonal antibody linked to a drug called tesirine that targets CD19 receptors on cancer cells to deliver the drug payload1, while rituximab is a monoclonal antibody that binds to CD20 on B cells and certain cancer cells1.

The primary objective is to obtain a preliminary estimate of the anti-tumor activity of loncastuximab tesirine and rituximab in newly diagnosed double-expressor lymphoma and double-hit lymphoma1. Secondary objectives include assessing safety and tolerability of the lonca-R and DA-EPOCH-R combination as coded by Common Terminology Criteria for Adverse Events version 5.01.

The study is designed as a single-group, phase 2, treatment trial with planned enrollment of 24 participants, and is being conducted at two sites in the United States: University of California Davis Comprehensive Cancer Center in Sacramento and UC San Diego Moores Cancer Center in San Diego1. The primary outcome is complete response rate, evaluated per 2014 Lugano criteria from first dose through cycle 21.

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.